“The US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Shilpa Medicare Ltd's formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India which was inspected between 11th November and 30th November 2017,” Shipla Medicare on Saturday, March 16, 2018, said in a regulatory filing.
FDA has determined that the inspection classification of this facility is VAI (voluntary action indicated) and accordingly EIR issued. The earlier status of formulation unit is maintained, it added.
The stock hit a 52-week low of Rs 401 on the BSE on March 8, 2018 in intra-day trade. It had underperformed the market by falling 32% in past five months, against 2% rise in the S&P BSE Sensex.
In December 2017, the company had received 10 observations from USFDA in relation to SEZ formulation facilities situated at Jadcherla, Telangana. Out of the 10 observations, 7 were related to improvement in procedures and practices and 3 observations were related to setting of analytical specifications, test procedures and method validation.
At 09:43 am; the stock was trading 6% higher at Rs 484 as compared to a marginal 0.03% rise in the benchmark index. A combined 88,663 shares changed hands on the counter on the BSE and NSE.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
-
Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
-
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in